Goldman Sachs has reiterated its ‘Sell’ rating on Metropolis Healthcare, increasing the target price to ₹1,775 from ₹1,725, which suggests a potential 17% downside from the current market price (CMP) of ₹2,151.70. Key insights from Goldman Sachs’ analysis include:
- Q2 Performance: Metropolis reported an in-line Q2, described as a decent quarter.
- Challenges Ahead: Goldman Sachs sees multiple challenges for the company in the medium term, which could impact its growth and profitability.
- Valuation Concerns: Despite the target price revision, Goldman maintains a ‘Sell’ stance due to rich valuations, which it views as a risk in the current environment.
Disclaimer: This information is for informational purposes only and does not constitute financial advice.
